How that compares with PlexusDx protocols For context, PlexusDx runs month-to-month at $189 for Semaglutide Injection and $289 for Tirzepatide Injection, narrowly under Eden's $198 and $298 all-in, and also carries Semaglutide Oral at $289/month and Tirzepatide Oral at $349/month, formats Eden does not offer
Subscriptions are available, but they dont save you any money
The investment often pays for itself through faster recovery and improved training outcomes
Key findings: CagriSema achieved up to 23% weight loss at 84 weeks Tirzepatide showed numerical superiority (~25.5%) The trial did not meet non-inferiority vs tirzepatide Clinical interpretation: Despite not meeting the primary endpoint, an important signal emerges: targeting multiple biological pathways remains a compelling strategy Why this matters: Reinforces obesity as a complex neuroendocrine disease Supports the concept that multi-hormonal approaches may better impact the defended weight set point Moves the field closer to precision, mechanism-based therapies Safety: Consistent with the GLP-1 class Mainly gastrointestinal adverse events, generally mild to moderate and transient Whats next: Ongoing development with higher-dose CagriSema Expansion of the REDEFINE program FDA decision expected by late 2026 Take-home message: The future of obesity treatment lies not in a single pathway, but in strategically combining mechanisms to sustainably shift weight biology
Indicatively, BPC 157 improves the healing of the skin wounds, muscle, tendon, ligament, and bone injuries
